ReportWire

Tag: schizophrenia

  • Nick Reiner placed in mental health conservatorship in 2020: report – National | Globalnews.ca

    [ad_1]

    New details have come to light about Nick Reiner’s mental health in the years before he was charged with two counts of first-degree murder in the deaths of his parents, Rob and Michele Singer Reiner.

    According to a report published by the New York Times on Thursday, Reiner, 32, entered into a mental health conservatorship in 2020 that ended in 2021. The outlet cited confirmation from a clerk at the Los Angeles Superior Court.

    Reiner’s appointed conservator, Steven Baer, told the outlet that mental illness “is an epidemic that is widely misunderstood, and this is a horrible tragedy.”

    Reiner was allegedly put under an L.P.S. conservatorship — based on a 1967 law, the Lanterman-Petris-Short Act — that established a new process for involuntary psychiatric treatment in California, according to the report.

    Story continues below advertisement

    A conservatorship, known in some states as a guardianship, is an involuntary status usually reserved for senior or very ill people who are suffering from dementia or otherwise incapacitated and unable to make decisions for themselves. (Singer Britney Spears was famously under a conservatorship for 13 years.)

    L.P.S. conservatorships typically originate from an involuntary psychiatric hospitalization and are initiated by a doctor.

    The conservator makes decisions about medical matters, such as treatment and medications for the person under conservatorship, which typically lasts one year before the conservator may seek renewal.

    Two people familiar with Reiner’s health spoke with the New York Times on condition of anonymity and alleged that Reiner had been diagnosed at different times with schizophrenia and schizoaffective disorder, a serious mental illness blending symptoms of schizophrenia with mood disturbances.

    Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day.

    Get daily National news

    Get the day’s top news, political, economic, and current affairs headlines, delivered to your inbox once a day.

    “The medication Mr. Reiner had been taking was effective, the other person said, but side effects led him to switch to a new medication about a month before his parents were killed,” the report claims.

    Story continues below advertisement

    In December, the Los Angeles Times reported that Reiner had been prescribed medication for schizophrenia. He is currently being held at the Twin Towers Correctional Facility in downtown Los Angeles.

    Alan Jackson, the lawyer who had been representing Reiner, removed himself from the case last week ahead of Reiner’s second appearance in Los Angeles Superior Court for his scheduled arraignment.

    Jackson announced that he was withdrawing from the case, and Reiner will now be represented by public defender Kimberly Greene.


    “Be very, very clear about this — my team and I remain deeply, deeply committed to Nick Reiner and to his best interests,” Jackson told reporters outside the courthouse. “In fact, we know, we’re not just convinced, we know that the legal process will reveal the true facts of the circumstances surrounding this case.”

    “What we’ve learned — and you can take this to the bank — is that pursuant to the law in this state, Nick Reiner is not guilty of murder. Print that,” Jackson added.

    Reiner’s scheduled arraignment has now been postponed to Feb. 23 following Jackson’s withdrawal from the case.

    Following the news, Reiner’s family told the New York Times in a statement that they “have the utmost trust in the legal process and will not comment further on matters related to the legal proceedings.”

    Story continues below advertisement

    Reiner’s scheduled appearance in court took place more than three weeks after his 78-year-old father, a well-known movie director, and 70-year-old mother were found dead with stab wounds in their home in the upscale Brentwood section of Los Angeles on Dec. 14, 2025.

    He did not enter a plea during a brief first court appearance on Dec. 17. Jackson told the court it was “too early” to enter a plea and that he had already agreed with the prosecution to delay the arraignment until January.

    Reiner also faces a special allegation that he personally used a dangerous and deadly weapon — in this case a knife, Los Angeles County District Attorney Nathan Hochman announced at a news conference on Dec. 16.

    These charges carry a maximum sentence of life in prison without the possibility of parole, or the death penalty. No decision about the death penalty has been made as of yet, Hochman added.

    — With files from The Associated Press

    Curator Recommendations

    © 2026 Global News, a division of Corus Entertainment Inc.

    [ad_2]

    Katie Scott

    Source link

  • Social Media Applauds Keyshia Ka’oir After She & Gucci Mane Opened Up About Managing His Schizophrenia (WATCH)

    [ad_1]

    Social media is applauding Keyshia Ka’oir after she and Gucci Mane opened up about managing his schizophrenia.

    RELATED: Hol’ Up! Keyshia Ka’oir Responds After Rick Ross’ Ex Alleges She Was Involved With The Rapper While Gucci Mane Was Incarcerated

    Keyshia Ka’oir & Gucci Mane Open Up About How She Manages His Schizophrenia

    On Monday, October 20, a new episode of ‘The Breakfast Club’ was released via YouTube featuring Gucci Mane and Keyshia Ka’oir as guests. During the episode, Ka’oir was asked about how she was able to protect Gucci and their businesses amid the rapper’s diagnosis.

    In turn, Ka’oir explained that she has a “system” which consists of taking his phone and deleting his apps.

    “Even if I gotta change his password, I’m changing it. ‘Cause I don’t need the public to know that he’s having an episode. You realize, you never know about any of the episodes… because I control that,” she explained.

    In addition, Ka’oir explained that she “controls everything at home.”

    “And now, before the episodes come — I catch it. So that’s why he hasn’t had another one. And how you catch that is: he doesn’t speak to you. He wants to be left alone. He doesn’t eat. He does not sleep…”

    Once Ka’oir mentions to Gucci that he hasn’t been speaking to her, and identifies that he’s having an episode, she explained, Gucci is able to “snap out of it” and catch himself.

    Watch their full statements, including Gucci opening up more about his symptoms.

    Social Media Is Applauding The Rapper’s Wife

    Social media users entered TSR’s comment section, applauding Keyshia Ka’ouir for how she manages Gucci Mane’s schizophrenia.

    Instagram user @abbytinklouis wrote, Thats the kind of woman Kanye needed to married”

    While Instagram user @marcquiajaina added,They was calling his wife his ‘handler’ but she’s really his protector.”

    Instagram user @ohhhglory wrote, He that findeth a good wife, .…………👏👏👏👏”

    While Instagram user @therealmarsena added, How brave of him to talk about his illness so openly! I wish more took mental health seriously.. prayer alone will not fix it!”

    Instagram user @paradiseparis wrote, This is what it looks like to love a person”

    While Instagram user @terryderon added, Hearing him actually explain and articulate what he was thinking and dealing with makes his success even that more impressive. The story of how she flipped his money when he went to jail was impressive. But hearing her explain how she protects him from himself is even more impressive than that!!! Salute!!!”

    Instagram user @gorgeousstrands wrote, Yes she’s doing a great job but being with someone who also fully trusts her to manager him in this way is also super important! It wouldn’t be this easy with someone that fights her about his phone and passwords lol. It takes TWO!…”

    While Instagram user @askaledavis added, This level of transparency is so commendable. They’re going to help so many people. ❤️❤️”

    Instagram user @miaray wrote, What a wife! 🥹🙏🏽”

    While Instagram user @ayyyrr15 added, If a woman doesn’t recognize certain patterns in her man she doesn’t care about him. Keyshia loves him ❤️”

    Instagram user @toodiebruce wrote, This is beautiful! Speaking about his mental illness publicly is so refreshing to see. Transparency save lives! This is what unconditional love looks like! Continued blessings to them both 🫶🏾🙏🏾”

    Before Opening Up About Gucci Mane’s Schizophrenia, Keyshia Ka’oir Turned Heads With Sultry ‘Fit Check

    Months before Keyshia Ka’oir and Gucci Mane opened up about his schizophrenia, she was turning heads with a sultry ‘fit check. As The Shade Room previously reported, in August, Ka’oir stepped out rocking a lace top and bottom accessorized with a feathered skirt.

    Ultimately, Ka’oir’s ‘fit had some social media users saying she looked “gaudy & tacky” while others were saying she was “killin’ it.”

    RELATED: Too Much? Keyshia Ka’oir Sparks Mixed Reactions With Sultry ‘Fit Check Footage (WATCH)

    What Do You Think Roomies?

    [ad_2]

    Jadriena Solomon

    Source link

  • New Approach Targets Social Skills to Help Schizophrenia Patients Heal

    [ad_1]

    SUNDAY, Oct. 12, 2025 (HealthDay News) — A new study from Case Western Reserve University suggests a major shift in schizophrenia treatment: One that focuses on helping patients better interpret social cues.

    “We’ve been treating schizophrenia with a one-size-fits-all approach for decades,” Jessica Wojtalik, an assistant professor at the Cleveland university’s school of applied social sciences, said in a news release. “Now we have a specific target that could help young patients get their lives back on track much faster.”

    The findings — published recently in the journal Psychiatry Research — identify a key brain function known as social inference skills as a potential new focus for early treatment. It’s a person’s ability to “read between the lines” in social situations.

    Schizophrenia, a serious mental illness that affects how people think, feel and behave, often begins during the teenage years when the brain is still developing, according to the National Institute of Mental Health

    This timing can have lifelong effects on relationships, learning and emotional control.

    The new study found that improving patients’ ability to interpret tone, body language and sarcasm — skills essential for navigating everyday interactions — could help them function better in everyday life.

    “Think of social inference as your brain’s social detective work,” lead author Anju Kotwani, a doctoral student in applied social sciences at Case Western, said in a news release. “It’s how you figure out what someone really means when they say ‘fine’ in a certain tone or how you know when someone is being sarcastic versus serious.”

    The research team studied 102 patients in the early stages of schizophrenia and found that social cognition (the brain’s ability to understand and respond to social cues) serves as a critical link between basic thinking skills and day-to-day functioning.

    Their results suggest that training programs that strengthen social inference skills through structured computer games or guided worksheets could be more effective than traditional methods focused on memory or attention alone.

    Researchers hope the findings will help shape new community-based treatment programs aimed at young folks newly diagnosed with schizophrenia.

    “Addressing both thinking skills and social understanding offers the best hope for functional recovery in early schizophrenia,” Kotwani said.

    SOURCE: Case Western Reserve University, news release, Oct. 8, 2025

    Copyright © 2025 HealthDay. All rights reserved.

    [ad_2]

    HealthDay

    Source link

  • Mental Illness Linked to Higher Heart Disease Risk and Shorter Lives

    [ad_1]

    A sweeping review published in The Lancet Regional Health—Europe has drawn a direct line between mental health disorders and cardiovascular disease (CVD), showing that individuals living with psychiatric conditions face not only a higher risk of heart problems but also a shorter life expectancy. The paper, authored by researchers from Emory University, the University of Copenhagen, the University of Leeds, and others, concludes that people with depression, schizophrenia, bipolar disorder, post-traumatic stress disorder (PTSD), and anxiety live 10 to 20 years less on average, mainly due to heart disease.

    A Bidirectional Threat

    The analysis shows that the connection between mental health and cardiovascular disease is not one-directional. The stress of a heart attack or stroke can trigger psychiatric disorders, while psychiatric conditions themselves set the stage for heart disease. The risks are striking as depression raises cardiovascular risk by 72 percent, schizophrenia by 95 percent, bipolar disorder by 57 percent, PTSD by 61 percent, and anxiety disorders by 41 percent. “It is important to understand that stress, anxiety, and depression can affect your heart, just like other physical factors,” the paper noted, offering guidance for how doctors might begin crucial conversations with patients.

    A Widespread Burden

    One in four people will experience a mental health disorder in their lifetime, yet many go untreated and often receive poor cardiovascular care. “Despite having more interactions with the healthcare system, they undergo fewer physical checkups and screenings and receive fewer diagnoses and treatments for CVD and its risk factors,” the authors reported. According to 2023 U.S. survey data cited in the study, more than half of those who met the criteria for a mental health disorder had not received any treatment, with even lower rates among non-White populations.

    Shared Risk Factors

    Researchers identified a cluster of overlapping drivers—poverty, trauma, social disadvantage, substance use, and poor access to health care—that amplify the dual risks of mental illness and cardiovascular disease. Lifestyle behaviors such as smoking, poor diet, physical inactivity, and disrupted sleep patterns are also more common among people with psychiatric conditions. The biological picture is equally troubling. Dysregulation of the stress response system, inflammation, and autonomic nervous system dysfunction are all pathways through which psychiatric disorders may accelerate cardiovascular decline.

    Breaking the Cycle

    The study calls for a fundamental shift in medical practice. “For the best care, an integrated approach is needed to address the complex needs of this vulnerable population,” the authors wrote. “Such approach should offer enhanced support and interdisciplinary care encompassing mental, cardiovascular, and behavioral health, as well as consideration of the social needs and barriers to care.” Among the interventions reviewed, exercise emerged as one of the most effective treatments, improving both mood and heart health. Evidence shows that physical activity can deliver improvements on par with or greater than medication or psychotherapy for depression. Mind-body practices like yoga and mindfulness, while requiring more evaluation, also show promise for improving outcomes across both mental and cardiovascular health.

    A Call to Integrate Care

    The authors stressed that progress depends on healthcare systems breaking down the wall between physical and mental health. For decades, treatment has been siloed, with psychiatrists focusing on the mind and cardiologists on the body. That separation, the study finds, has left millions vulnerable. The authors argue for expanded insurance coverage, investment in housing and employment stability, and the inclusion of psychiatric patients in cardiovascular research. Above all, they call for integrated care models that recognize the tight link between mental and cardiovascular health.

    Global Health Priority

    The stakes are enormous. The World Health Organization has set a 2025 target to reduce the global burden of cardiovascular disease. The paper argues that this goal cannot be reached without directly addressing the disparities faced by those with psychiatric disorders.

    “Closing the disparity gap for individuals with mental health disorders would be consistent with the World Health Organization 2025 targets of reducing the global burden of CVD,” the researchers concluded. “Reducing these disparities would also uphold the rights of people with mental health disorders to achieve the highest possible level of health and to fully participate in society and the workforce.”

    [ad_2]

    Stacy M. Brown, NNPA Newswire Senior National Correspondent and NNPA

    Source link

  • Boosting BDNF Levels in Our Brain to Treat Depression  | NutritionFacts.org

    [ad_1]

    We can raise BDNF levels in our brain by fasting and exercising, as well as by eating and avoiding certain foods.

    There is accumulating evidence that brain-derived neurotrophic factor (BDNF) may be playing a role in human depression. BDNF controls the growth of new nerve cells. “So, low levels of this peptide could lead to an atrophy of specific brain areas such as the amygdala and the hippocampus, as it has been observed among depressed patients.” That may be one of the reasons that exercise is so good for our brains. Start an hour-a-day exercise regimen, and, within three months, there can be a quadrupling of BDNF release from our brain, as seen below and at 0:35 in my video How to Boost Brain BDNF Levels for Depression Treatment.

    This makes sense. Any time we were desperate to catch prey (or desperate not to become prey ourselves), we needed to be cognitively sharp. So, when we’re fasting, exercising, or in a negative calorie balance, our brain starts churning out BDNF to make sure we’re firing on all cylinders. Of course, Big Pharma is eager to create drugs to mimic this effect, but is there any way to boost BDNF naturally? Yes, I just said it: fasting and exercising. Is there anything we can add to our diet to boost BDNF?

    Higher intakes of dietary flavonoids appear to be protectively associated with symptoms of depression. The Harvard Nurses’ Health Study followed tens of thousands of women for years and found that those who were consuming the most flavonoids appeared to reduce their risk of becoming depressed. Flavonoids occur naturally in plants, so there’s a substantial amount in a variety of healthy foods. But how do we know the benefits are from the flavonoids and not just from eating more healthfully in general? We put it to the test.

    Some fruits and vegetables have more flavonoids than others. As shown below and at 1:51 in my video, apples have more than apricots, plums more than peaches, red cabbage more than white, and kale more than cucumbers. Researchers randomized people into one of three groups: more high-flavonoid fruits and vegetables, more low-flavonoid fruits and vegetables, or no extra fruits and vegetables at all. After 18 weeks, only the high-flavonoid group got a significant boost in BDNF levels, which corresponded with an improvement in cognitive performance. The BDNF boost may help explain why each additional daily serving of fruits or vegetables is associated with a 3 percent decrease in the risk of depression. 

    What’s more, as seen here and at 2:27 in my video, a teaspoon a day of the spice turmeric may boost BNDF levels by more than 50 percent within a month. This is consistent with the other randomized controlled trials that have so far been done. 

    Nuts may help, too. In the PREDIMED study, where people were randomized to receive weekly batches of nuts or extra-virgin olive oil, the nut group lowered their risk of having low BDNF levels by 78 percent, as shown below and at 2:46.

    And BDNF is not implicated only in depression, but schizophrenia. When individuals with schizophrenia underwent a 12-week exercise program, they got a significant boost in their BDNF levels, which led the researchers to “suggest that exercise-induced modulation of BDNF may play an important role in developing non-pharmacological treatment for chronic schizophrenic patients.”

    What about schizophrenia symptoms? Thirty individuals with schizophrenia were randomized to ramp up to 40 minutes of aerobic exercise three times a week or not, and there did appear to be an improvement in psychiatric symptoms, such as hallucinations, as well as an increase in their quality of life, with exercise. In fact, researchers could actually visualize what happened in their brains. Loss of brain volume in a certain region appears to be a feature of schizophrenia, but 30 minutes of exercise, three times a week, resulted in an increase of up to 20 percent in the size of that region within three months, as seen here and at 3:46 in my video

    Caloric restriction may also increase BDNF levels in people with schizophrenia. So, researchers didn’t just have study participants eat less, but more healthfully, too—less saturated fat and sugar, and more fruits and veggies. The study was like the Soviet fasting trials for schizophrenia that reported truly unbelievable results, supposedly restoring people to function, and described fasting as “an unparalleled achievement in the treatment of schizophrenia”—but part of the problem is that the diagnostic system the Soviets used is completely different than ours, making any results hard to interpret. There was a subgroup that seemed to correspond to the Western definition, but they still reported 40 to 60 percent improvement rates from fasting, but fasting wasn’t all they did. After the participants fasted for up to a month, they were put on a meat- and egg-free diet. So, when the researchers reported these remarkable effects even years later, they were for those individuals who stuck with the meat- and egg-free diet. Evidently, the closer the diet was followed, the better the effect, and those who broke the diet relapsed. The researchers noted: “Not all patients can remain vegetarian, but they must not take meat for at least six months, and then in very small portions.” We know from randomized controlled trials that simply eschewing meat and eggs can improve mental states within just two weeks, so it’s hard to know what role fasting itself played in the reported improvements.

    A single high-fat meal can drop BDNF levels within hours of consumption, and we can prove it’s the fat itself by seeing the same result after injecting fat straight into our veins. Perhaps that helps explain why increased consumption of saturated fats in a high-fat diet may contribute to brain dysfunction—that is, neurodegenerative diseases, long-term memory loss, and cognitive impairment. It may also help explain why the standard American diet has been linked to a higher risk of depression, as dietary factors modulate the levels of brain-derived neurotrophic factor.

    [ad_2]

    Michael Greger M.D. FACLM

    Source link

  • New Study Links Mental Illness, Recent Trauma and Substance Use to Risk of Officer-Involved Shootings

    [ad_1]

    A new study provides compelling evidence that persons with serious mental illness, recent trauma or substance use disorders are significantly more likely to be shot by law enforcement. Led by Dr. Liam O’Neill of the University of North Texas, The Role of Mental Health, Recent Trauma, and Suicidal Behavior in Officer-Involved Shootings: A Public Health Perspective takes a public health perspective to examine officer-involved shootings using seven years of statewide hospital data.

    The study compared 177 civilians who were hospitalized following an officer-involved shooting to over 33,000 persons of comparable ages who were hospitalized after car accidents. Young males age 20-39 were found to be at greatest risk. Almost one-fourth of study subjects had a diagnosed mental illness. Schizophrenia alone tripled the risk of being shot. Methamphetamine use disorder emerged as a major risk factor, increasing the odds of being shot by police more than threefold. Recent bereavement – the loss or disappearance of a family member – was linked to an eightfold increase in risk. Methamphetamine use increased significantly during the study period (2015-2023) and was a factor in 15 percent of law enforcement encounters.

    Importantly, the study also identified protective factors. Persons with commercial health insurance or Medicaid were significantly less likely to be involved in an officer-involved shooting, underscoring the importance of access to primary health care and mental health services.

    “Law enforcement officers are often the first responders to psychiatric crises, but they shouldn’t be the only line of defense,” said Dr. O’Neill. “Addressing untreated schizophrenia or methamphetamine addiction before it escalates to police involvement could save lives.”

    This study is among the first to use detailed hospital records – rather than police or media reports – to identify the pre-existing conditions of persons involved in police shootings. This approach allowed the authors to identify underlying clinical and social factors that might otherwise be missed, such as recent trauma or a history of suicide attempts. More than 10 percent of study subjects had one or more markers of social vulnerability, including being disabled, being homeless, having post-traumatic stress disorder or hepatitis C. There was substantial overlap among mental illness, substance use, chronic disease, and social disadvantage. More than half of study subjects had at least one of these risk factors, and one in 10 had two or more.

    The researchers call for broader use of hospital data to strengthen public health surveillance and guide policy. They also emphasize the need for coordinated efforts among law enforcement, public health, and social services. It also reinforces the need to expand crisis intervention training and community-based mental health services to reduce the risk of violent encounters.

    The study analyzed de-identified hospital records from the State of Texas. It was just published online in the International Journal of Environmental Research and Public Health. It contributes to a growing body of research emphasizing the preventable nature of many officer-involved shootings.

    Source: Dr. Liam O’Neill

    [ad_2]

    Source link

  • A promising schizophrenia drug showed mixed results. What does that mean for patients?

    A promising schizophrenia drug showed mixed results. What does that mean for patients?

    [ad_1]

    Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

    The results underscore the difficulties in treating schizophrenia, a severe mental illness that can cause people to hear voices, feel paranoid and withdraw from others. High dropout rates are typical in schizophrenia drug studies.

    Finding a drug that works can be a long ordeal punctuated by crises and hospitalizations. Side effects of existing medications — weight gain, tremors, restlessness — cause some people to stop taking medicine and relapse.

    There’s been great hope among doctors for Cobenfy, which was approved in September, because it acts in the brain differently than other schizophrenia drugs. Instead of blocking dopamine receptors, Cobenfy’s main ingredient, xanomeline, works on a different receptor that indirectly blocks dopamine release.

    Cobenfy also contains trospium, which blocks some of the side effects. The most common are nausea, vomiting and indigestion. In contrast to the weight gain seen with other schizophrenia drugs, people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb.

    Dr. John Krystal of Yale University has led research on other schizophrenia drugs but was not involved in the new studies. He noted that just 10% to 20% of participants in the new studies dropped out because of side effects.

    “That is pretty good,” he said, noting that fewer or milder side effects could mean people will stay in treatment longer. That could mean fewer problems associated with untreated mental illness: substance use, homelessness and unemployment.

    So why did some patients stick with treatment while others dropped out? Krystal said it will be important to understand more about that as doctors start prescribing the drug.

    The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials and other safety data. The latest results announced Thursday at the Psych Congress meeting in Boston come from two longer studies, providing a fuller picture.

    In one study, focused on severely ill patients, 78% dropped out, leaving only 35 people for the final analysis. In the other, focused on more stable people, 51% left the study, leaving 283 who took the drug for a year.

    “It’s not any higher or any lower than what we typically see” in schizophrenia studies, said Dr. Greg Mattingly of Washington University School of Medicine in St. Louis. Mattingly is a consultant for Bristol Myers Squibb and a researcher on one of the studies.

    In the more severely ill group, 69% of people had a meaningful improvement in their symptoms at the end of the year. In the other group, 30% saw a meaningful benefit.

    Results of interviews with a sample of study participants conducted by an independent research team and shared by Bristol Myers Squibb showed the likelihood of continuing treatment. After six months, 36 said they would continue taking Cobenfy after the trial if given the option; 10 said they would not. Some participants said the drug reduced the voices while others said it didn’t work for them.

    The estimated yearly cost for Cobenfy is $22,500 compared to $540 for a generic antipsychotic. Krystal and others worry that insurers will require people to try cheaper drugs first before covering Cobenfy. Most patients’ out-of-pocket costs will be much lower, depending on insurance and other factors.

    One cheaper generic called clozapine is widely considered one of the best treatments for schizophrenia, Krystal said. It is underused in the U.S. compared to some other countries because of a cumbersome blood testing program.

    The FDA started the blood tests to watch for the risk of severe neutropenia, a rare side effect which can be fatal. But doctors and families have told the FDA that patients have relapsed when their clozapine was withheld or delayed because of the testing requirements.

    Sally Littlefield, 29, of Alameda, California, said what works for her is a monthly injection of a long-acting antipsychotic medication. Littlefield, who has schizophrenia and bipolar disorder, wants to learn more about the experiences of people who’ve taken Cobenfy and not just from players with a financial stake.

    Mindy Greiling of Roseville, Minnesota, wants to see data on how Cobenfy compares to clozapine, which works for her 47-year-old son, Jim. Weight gain was a problem for him, but since taking diabetes medication, he’s back to his normal weight, Greiling said.

    Cobenfy “is getting a lot of ballyhoo, as any new drug does,” Greiling said. “It’s just a nonstarter for me unless it turns out that it’s better than clozapine.”

    ___

    The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • Marijuana and Schizophrenia?  | NutritionFacts.org

    Marijuana and Schizophrenia?  | NutritionFacts.org

    [ad_1]

    The evidence linking cannabis use to psychotic disorders is considered strong enough to warrant a public health warning. 
      
    “Even as proponents of [cannabis] legalization contend that smoked marijuana is a harmless natural substance that improves the quality of life, a growing body of evidence links it in a small but significant number of users to…the induction or aggravation of psychosis.” “Psychotic disorders are arguably the most serious of mental illnesses, the best known being schizophrenia.” “Schizophrenia, an illness that is characterized by delusions, hallucinations, and odd behavior, is among the top 10 leading causes of disability in the United States. It affects approximately 1% of the general population.” Can cannabis cause it? 
     
    As I discuss in my video Does Marijuana Cause Schizophrenia?, over the last half-century, “nearly 2,000 studies have been published on this topic…and the pro-psychotic effects of cannabis have dominated media reporting about this drug. But how clear is the link?” Population studies have “consistently demonstrated a strong, positive, and dose-dependent association between cannabis use and the risk of psychotic disorders.” Indeed, studies have shown that the more cannabis people use, the more likely they are to be psychotic, as seen in a chart below and at 1:10 in my video

    However, that doesn’t mean cannabis is the cause. It could just be a correlation or even a consequence of the disease. “The link between cannabis and psychosis is well established,” but it may be the case that patients with mental health problems self-medicate and “use cannabis to relieve their distress.” 

    As you can see below and at 1:38 in my video, there isn’t only a link between cannabis and psychosis in snapshot-in-time cross-sectional studies, but in cohort studies as well, where people are followed over time. Research has shown that cannabis use often precedes psychosis, not the other way around. Now, it goes without saying that “the vast majority of people who use cannabis do not develop psychotic disorders such as schizophrenia, and many people diagnosed with such disorders have never used cannabis.” But, overall, these studies are considered to be “strong enough evidence to warrant a public health message that cannabis use can increase the risk of psychotic disorders.”   


    There is another potential explanation: Even though cannabis use precedes schizophrenia, could it be that whichever genes drive schizophrenia also make it more likely you start smoking pot? The biggest strike against the cannabis-schizophrenia link is country-by-country ecological studies that don’t seem to show more disease in areas where there’s more use. And, overall, schizophrenia rates seem to have remained stable or even gone down worldwide since the 1960s, even though there’s been a big bump in cannabis use since then.  

    If about 10 percent of schizophrenia cases are attributable to marijuana use and there’s been a fourfold increase in use, why hasn’t there been a 40 percent increase in the prevalence of schizophrenia? The problem with that argument is “there is little reliable evidence on the temporal [true] trends in the incidence of schizophrenia, so it is difficult to know whether this statement is true or not.” Perhaps it’s more of an issue with potency rather than just cannabis in general. Indeed, “the incidence of schizophrenia is higher in countries…where high-potency cannabis has taken over the market compared with countries…where more traditional forms of cannabis are smoked.” The bottom line is you don’t know until you put it to the test. 
     
    You can’t just randomize kids to cannabis, but, in a way, Mother Nature set up a natural experiment for us. There are genes that kids randomly get that can increase their likelihood of smoking pot. Do those kids then go on to have a higher risk of schizophrenia? Yes, research “findings strongly support” all of those population studies that suggest “cannabis plays a causal [cause-and-effect] role in the development of schizophrenia.” Okay, but by how much? 
     
    Let’s break it down. Even if cannabis use doubles the risk, that would mean only going from a 7-in-1,000 chance of developing a psychosis to 14 in 1,000. So, going from a 1 in 140 chance to a 1 in 70 chance. It would be different if schizophrenia runs in your family, where a doubling of risk could mean going from a one-in-ten chance to one in five, but, on a population scale, it could take thousands of cannabis users quitting to prevent a single case of schizophrenia. So, from a public health standpoint, “addiction is a far more common problem.” Researchers “estimate that people who try cannabis are ninefold more likely to become addicted to it”—even though that itself is relatively rare—“than to develop psychosis in their lifetime.” 

    I have an entire series of videos on cannabis, which I originally released in a webinar and downloadable digital DVD. See related videos below.



    [ad_2]

    Michael Greger M.D. FACLM

    Source link

  • Science Weighs In On Marijuana And Being Psychotic

    Science Weighs In On Marijuana And Being Psychotic

    [ad_1]

    There are a number of myths about marijuana. For the canna-curious, you have to look at what data says to the real answer

    But one of the biggest fears from those with little experience—will I have an adverse reaction to smoking pot? For the canna-newbie and the canna-curious, it might be a wee bit worrying.   Science weighs in on marijuana and being psychotic.  Ignore the myths and look at the data so you consume without a concern.

    Canadian scientists tried to answer that question by determining if an individual’s genetic makeup could determine how they’d respond to THC, the cannabinoid responsible for inducing psychoactive sensations. What genetic technology expert John Lem of Lobos Genetics discovered was that genes could predict several key factors: your body’s metabolization of the drug, whether cannabis was more likely to induce paranoia into your systems, as well as the possibilities of memory loss and developing schizophrenia.

    RELATED: Can I Get High From Second-Hand Marijuana Smoke?

    All scientists would have to do, Lem attests, is a simple cheek swab that would test three different genes that could answer all those questions.

    “Looking into the science, we came to the conclusion that there is actually a genetic basis for someone’s reaction to THC,” Lem told CBC. “”If people understand how their body reacts to cannabis, that’s a good thing,” he added.

    However, another expert cautioned that such a genetic test could provide all the answers with 100% accuracy. Dr. Bernard Le Foll, a team member with the Centre of Addiction and Mental Health that created recommendations around cannabis usage, was quick to remind everyone that “there has been limited research done on cannabis.” He urged the need for tests with a larger number of participants before drawing any substantive conclusions.

    In addition, Le Foll said more factors are at play when understanding the body’s reactions to a type of drug like cannabis. Maybe in the future we’ll be better at accurately predicting someone’s response to marijuana, though “we’re not there just yet.”

    RELATED: The Ultimate Newbie’s Guide To Marijuana

    “The type of environment, the type of previous drug exposure, the dose — that is all very important, possibly more important than genetics,” added Le Foll.

    While we can’t fully know how cannabis will affect each individual, Lem added his test is only to help consumers make better decisions. As edible products hit stores this fall in Canada, it’s important people know not to take more than they need. But I’m not sure we needed a genetics test to help consumers understand not to be gluttons when using marijuana.

    [ad_2]

    Brendan Bures

    Source link

  • I Kept My Schizophrenia A Secret For 20 Years. Everything Changed When I Told A Friend.

    I Kept My Schizophrenia A Secret For 20 Years. Everything Changed When I Told A Friend.

    [ad_1]

    On a Thursday this past July, my husband and I drove to our county’s police academy training facility. A uniformed officer let us in. We were escorted through several hallways and into a conference room, where I was scheduled to speak representing our local National Alliance on Mental Illness office.

    Standing at the front of the room, I introduced myself first with all my accomplishments ― my recent graduation from a certificate program at Columbia University, the classes and workshops I teach, and a 25-year marriage. Then I added: “And I live with chronic paranoid schizophrenia, which is why I’m here to talk to you today.”

    I spoke for nearly an hour about the five types of hallucinations, the time the voices I heard identified themselves as God, Jesus and the Holy Spirit, and how I frequently thought my food was poisonous due to paranoia. I also touched on delusions I’ve had while psychotic.

    It’s important for officers to hear the information of someone with lived experience of a severe mental illness, because they so often encounter people who are in a mental health crisis in the course of their duties. I want them to understand that psychosis can make people act erratically, but that in many cases, these people can be treated successfully.

    To the best of my ability, I answered the officers’ questions about all aspects of living with schizophrenia. Many thanked me for coming, and for my vulnerability about a diagnosis that still has a great deal of misinformation and stigma associated with it.

    I kept my mental illness a secret from friends, in-laws and employers for almost 20 years. Since 2015, I’ve been making part of my income by telling the details of what it’s like to live with schizophrenia. I talk to law enforcement, nursing students and people studying marriage and family therapy, and at treatment facilities for those who are living with a similar diagnosis.

    Sharing my story helps certain groups understand mental illness better, and helps those living with it to feel less alone in their journey. The details I share can help professionals better understand what it’s like to have a break from reality.

    In my late 20s, I started to have thoughts that people were out to get me. As the paranoia increased, I stopped eating and sleeping. My relatives brought me to a hospital, but it was several days before I agreed to inpatient treatment. My hospital stay led to a diagnosis of bipolar disorder with psychotic features. At the time, I had a lot of denial and shame about the labels that became a part of my identity.

    Telling people I had a mental illness ― especially the men I was dating ― almost always ended with them disappearing from my life. I remember one man saying “I simply can’t handle this” when he ended things that very day, although I had never shown symptoms around him. I learned early on that mental illness was a deal breaker for many relationships.

    When I met my current husband, he also had reservations about my diagnosis. When we first dated, I wasn’t compliant with my medication, so I moved in and out of severe episodes. I attempted suicide twice, and had many episodes of hearing voices, paranoia and delusions.

    We stuck together, though, and even after he witnessed my symptoms, he kept supporting me. Not too long after we got together, I began to take my treatment more seriously, and we were able to focus on building a foundation for our soon-to-be marriage.

    By this time, I had learned not to mention my illness to people, so it became a secret between my husband and me. My family knew, but we didn’t tell my husband’s family. We didn’t tell any of his co-workers, or the friends we started to make after we bought a condo near the Los Angeles city limits.

    It wasn’t just the stigma and rejection I’d experienced that kept me silent about my struggles. It was also the internalization of the messages society had fed me about my condition and the people who live with it. I thought I was less lovable and likable, and that people who knew would view me as “crazy.”

    “Telling people I had a mental illness ― especially the men I was dating ― almost always ended with them disappearing from my life.”

    I had a stable period lasting almost 10 years, where I worked full-time, took classes and sat on committees for our city council. I had friends I worked with, hiked with and played racquetball with, and my husband and I regularly took trips overseas.

    My psychiatrist then decided there was something amiss with my diagnosis, and took me off all medication. Within a year, I was hallucinating 24/7, not sleeping, and having a total break from reality. I remained psychotic for six months before doctors could stabilize me again.

    These new doctors diagnosed me with chronic paranoid schizophrenia. It hit me and my husband like a punch. The day I got the news, we barely spoke. I remember my husband finally saying: “Well, there is nothing new about you today from yesterday.” That statement reassured me that he wasn’t going anywhere, even with this new information.

    We doubled down on the secret, though, and became even more protective of our personal life and the realities of my illness. I imagined that if people had rejected me when I told them I had bipolar disorder, it would be even worse if I told them I had schizophrenia.

    We’d kept this new secret between us and my family members for almost 10 years when my psychiatrist gave me a homework assignment to tell just one of my friends about my diagnosis. My psychiatrist recognized that if I was keeping a secret about something that affected my life so much, it would hold me back from being truly close to other people. She knew that hiding was isolating me from others.

    My husband and I talked about it for weeks. We went back and forth on whether we even wanted to disclose my illness to anyone, after living with it undercover for so long. We talked about losing friends. We talked about the fact that once we told one friend, more would find out.

    We finally decided to tell a social worker I had worked with closely at a YWCA.

    Over brunch, my voice shaking, I said: “I have schizophrenia.” At first, he was a little taken aback and had some questions, but the conversation did not take over our brunch date. That night, I wrote an essay about my experience with mental illness for an online magazine. When it was published, I posted a link to it on Facebook ― and that was how my in-laws, our co-workers, and even friends who’d known me since high school found out that I was living with a mental illness.

    We lost a few friends. I’m not sure if they thought “I can’t handle this,” like those early boyfriends, or if they were upset that we’d kept such a significant part of our lives from them. I often wonder if it hurt some people’s feelings to know that they were never as close to us as they may have thought because we were not living an authentic and fully open life.

    I felt vulnerable and scared about finally disclosing my secret, but there was also a massive relief. For the first time since my early 30s, I could talk about myself without hiding big chunks of my reality and who I am.

    I’ve been writing about life with schizophrenia ever since, and telling my story led to the position at NAMI that had me standing in front of dozens of police officers and explaining what it’s like to be in the middle of a mental health crisis.

    My secret has become my tool, and I no longer hide it. I talk about it each time someone asks me to, or any time mental health is the topic. I feel like I am using a difficult situation to make a difference in other people’s lives, which gives meaning to my experience of having schizophrenia, and turns it into something that isn’t entirely negative.

    I run into less stigma and more curiosity in 2023 than in all those years I lived splintered and cut off from true intimacy with relatives and friends. I am boldly myself ― my authentic self ― and I’m using that once tightly held secret to hopefully make the reality of mental illness less difficult for others like me.

    If you or someone you know needs help, call or text 988 or chat 988lifeline.org for mental health support. Additionally, you can find local mental health and crisis resources at dontcallthepolice.com. Outside of the U.S., please visit the International Association for Suicide Prevention.

    Do you have a compelling personal story you’d like to see published on HuffPost? Find out what we’re looking for here and send us a pitch.

    [ad_2]

    Source link

  • Appellate court rules that Missouri man with schizophrenia can be executed after all

    Appellate court rules that Missouri man with schizophrenia can be executed after all

    [ad_1]

    The planned execution of a 45-year-old Missouri man with schizophrenia is back on after an appellate court reversed course Saturday

    ByHEATHER HOLLINGSWORTH Associated Press

    FILE – This undated photo provided by the Missouri Department of Corrections shows Johnny Johnson. Johnson, 45, was convicted of first-degree murder in in the 2002 death of Casey Williamson in suburban St. Louis. (Missouri Department of Corrections via AP)

    The Associated Press

    The planned execution of a 45-year-old Missouri man with schizophrenia is back on after an appellate court reversed course Saturday.

    Johnny Johnson is scheduled to receive a lethal injection Tuesday at the state prison in Bonne Terre for killing 6-year-old Casey Williamson after trying to sexually assault her in 2002.

    With questions swirling about his mental competency, the execution was halted last Tuesday by a divided three-judge panel of the 8th U.S. Circuit Court. But after the Missouri Attorney General’s Office asked that the full court reconsider, that decision was reversed in a 7-3 ruling.

    The case will likely end up before the U.S. Supreme Court before the scheduled execution date.

    Attorneys for Johnson have claimed his schizophrenia prevents him from understanding the link between his crime and the punishment. They have also said Johnson has delusions about the devil using his death to bring about the end of the world.

    The Missouri Supreme Court in June declined to halt the execution based on the mental health claim. The attorney general’s office challenged the credibility of psychiatric evaluations of Johnson and contended that medical records indicate he is able to manage his mental illness through medication.

    Johnson lured the girl to an abandoned glass factory, even carrying her on his shoulders on the walk to the dilapidated site. When he tried to sexually assault her, Casey screamed and tried to break free. He killed her with bricks and rocks, then washed off in the Meramec River. Johnson confessed to the crimes.

    Casey’s disappearance set off a frantic search involving first responders and volunteers. Her body was found in a pit less than a mile (1.6 kilometers) from her home, buried beneath rocks and debris.

    The execution would be the fourth in Missouri this year.

    [ad_2]

    Source link

  • We know marijuana is linked to mental illness — so what are we doing? – Medical Marijuana Program Connection

    We know marijuana is linked to mental illness — so what are we doing? – Medical Marijuana Program Connection

    [ad_1]

    Original Author Link click here to read complete story..

    [ad_2]

    MMP News Author

    Source link

  • 10,000 brains in a basement: The dark and mysterious origins of Denmark’s psychiatric brain collection | CNN

    10,000 brains in a basement: The dark and mysterious origins of Denmark’s psychiatric brain collection | CNN

    [ad_1]

    Editor’s Note: Watch the special documentary, “World’s Untold Stories: The Brain Collectors,” November 12-13 on CNN International.



    CNN
     — 

    For years, there had been whispers. Rumors swirled; stories exchanged. It wasn’t a secret, but it also wasn’t openly discussed, adding to a legend almost too incredible to believe.

    Yet those who knew the truth wanted it out.

    Tell everyone our story, they said, about the brains in the basement.

    As a child, Lise Søgaard remembers whispers, too, though these were different – the family secret kind, hushed because it was too painful to speak it out loud.

    Søgaard knew little about it, except that these whispers centered on a family member who seemed to exist solely in one photograph on the wall of her grandparent’s house in Denmark.

    The little girl in the picture was named Kirsten. She was the younger sister of Søgaard’s grandmother, Inger – that much she knew.

    “I remember looking at this girl and thinking, ‘Who is she?’ ‘What happened?’” Søgaard said. “But also this feeling of a little bit of a horror story there.”

    As she grew into adulthood, Søgaard continued to wonder. One day in 2020, she went to visit her grandmother, now in her mid-90s and living at a care home in Haderslev, Denmark. After all that time, she finally asked about Kirsten. Almost as if Inger had been waiting for that very question, the floodgates opened, and out poured a story Søgaard never expected.

    Kirsten Abildtrup was born on May 24, 1927, the youngest of five brothers and her sister, Inger. As a child, Inger remembers Kirsten as quiet and smart, the two sisters sharing a close bond. Then, when Kirsten was around 14 years old, something began to change.

    Kirsten experienced outbursts and prolonged bouts of crying. Inger asked her mother if it was her fault, often feeling that way because the two girls were so close.

    “At Christmas, they were supposed to go on a visit to some family members,” Søgaard said, “but my great-grandmother and father, they stayed home and sent all of their children away except for Kirsten.”

    When they got back from that family visit, Søgaard said, Kirsten was gone.

    It was the first of many hospitalizations, and the start of a long and painful journey that would ultimately end in Kirsten’s death.

    The diagnosis: schizophrenia.

    Kirsten was first hospitalized towards the end of World War II, when Denmark and the rest of Europe were at last on the verge of peace.

    Like so many places, Denmark was also grappling with mental illness. Psychiatric institutions had been built across the country to provide care for patients.

    Doctors prepare a patient for electroshock therapy at Augustenborg Psychiatric Hospital in Denmark, 1943.

    But there was limited understanding of what was happening in the brain. The same year peace came to Denmark’s doorstep, two doctors working in the country had an idea.

    When these patients died in psychiatric hospitals, autopsies were routinely performed. What if, these doctors thought, the brains were removed – and kept?

    Thomas Erslev, historian of medical science and research consultant at Aarhus University, estimates that half of all psychiatric patients in Denmark who died between 1945 and 1982 contributed – unknowingly and without consent – their brains. They went to what became known as the Institute of Brain Pathology, connected to the Risskov Psychiatric Hospital in Aarhus, Denmark.

    Doctors Erik Stromgren and Larus Einarson were the architects. After roughly five years, said Erslev, pathologist Knud Aage Lorentzen took over the institute, and spent the next three decades building the collection.

    Dr. Larus Einarson, shown here teaching a class, was one of the co-founders of the brain collection at the Institute of Brain Pathology.

    The final tally would amount to 9,479 human brains – believed to be the largest collection of its kind anywhere in the world.

    In 2018, pathologist Dr. Martin Wirenfeldt Nielsen got a call. The brain collection, as it would come to be known, was on the move.

    A lack of funding meant it could no longer stay in Aarhus, but the University of Southern Denmark in the city of Odense had offered to pick up the mantle. Would Wirenfeldt Nielsen be interested in overseeing it?

    Pathologist Dr. Martin Wirenfeldt Nielsen now oversees the brain collection, housed in Odense, Denmark.

    “I’d sort of heard of it in the periphery,” Wirenfeldt Nielsen recalled. “But my first real knowledge about the vast extent of it was when they decided to move it down here … (because) how do you actually move almost 10,000 brains?”

    The yellowish-green plastic buckets housing each brain, preserved in formaldehyde, were placed into new white buckets that were sturdier for the transport, and hand-labeled in black marker with a number. And then the brains, give or take a few (no one knows where bucket #1 is, for example) made their way to their new home in a large basement room on the university’s campus.

    “The room wasn’t actually ready when they moved it down here,” Wirenfeldt Nielsen said. “The whole collection was just standing there, buckets on top of each other, in the middle of the floor. And that’s when I saw it for the first time … That was like, okay, this is something I’ve never seen before.”

    Eventually, the nearly 10,000 buckets were placed on rolling shelves, where they remain today – waiting – representing lives, and a range of psychiatric disorders.

    There are roughly 5,500 brains with dementia; 1,400 with schizophrenia; 400 with bi-polar disorder; 300 with depression, and more.

    What separates this collection from any other in the world is that the brains collected during the first decade are untouched by modern medicines – a time capsule of sorts, for mental illness in the brain.

    “Whereas other brain collections … (are) maybe specified for neurodegenerative diseases, dementia, tumors, or other things like that – we really have the whole thing here,” Wirenfeldt Nielsen said.

    But it has not been without controversy. In the 1990s, the Danish public got wind of the collection, which had been sitting idle since former director Lorentzen’s retirement in 1982.

    It would kick off one of the first major ethical science debates in Denmark.

    A history of The Brain Collection

    1945

    The Institute of Brain Pathology is founded, connected to the Risskov Psychiatric Hospital in Aarhus, Denmark

    Risskov, pictured here in the early 1900s.

    Credit: Museum Ovartaci

    1945-1982

    Nearly 9,500 brains are collected without permission from deceased psychiatric patients across the country

    Brains were collected and sent from Danish hospitals, including Rigshospitalet (pictured) in Copenhagen.

    Credit: Jesper Vaczy/Medical Museum

    1982

    The head of the brain collection, Knud Aage Lorentzen, retires. Nobody takes his place, and the collection sits untouched in a basement

    The brains, shown here in their original yellow buckets, would remain largely untouched for more than 20 years.

    Credit: Hanne Engelstoft

    1987

    The Danish Council of Ethics is established

    The Council of Ethics is an independent group formed to advise the Danish parliament (pictured here in 2016) on ethical matters.

    Credit: olli0815/iStock/Getty Images

    1991

    After the Council of Ethics says the brains can be used with certain restrictions in place, SIND (Denmark’s national association for psychiatric health) demands the brains be buried – sparking one of the first major ethical science debates in Denmark

    Some pieces of brain material are preserved in paraffin wax.

    Credit: Hanne Engelstoft

    2005

    Danish scientist Karl-Anton Dorph-Petersen takes over the collection’s daily maintenance at Aarhus

    Karl-Anton Dorph-Petersen helped revive and preserve the collection in the mid-2000s.

    Credit: Hanne Engelstoft

    2006

    The Council of Ethics goes against political and religious demands by ruling it is ethically sound to use deceased psychiatric patient brains for research without getting the consent of relatives. This time, SIND agrees

    The collection includes patient records and tissue preserved on slides, such as these.

    Credit: Hanne Engelstoft

    2017-2018

    A lack of funding threatens the brains, and the collection is saved by moving it to Odense, where Dr. Martin Wirenfeldt Nielsen takes over

    The brains were put into new white buckets to move to Odense, where they remain safely stored on rolling shelves.

    Credit: Samantha Bresnahan/CNN

    Source: Thomas Erslev, historian of medical science

    Graphic: Woojin Lee, CNN

    “There was a discussion back and forth, and one position was that we should destroy the collection – either bury the brains or get rid of them in any other ethical way,” said Knud Kristensen, the director of SIND, the Danish national association for mental health, from 2009 to 2021, and current member of Denmark’s Ethical Council. “The other position said, okay, we already did harm once. Then the least we can do to those patients and their relatives is to make sure that the brains are used in research.”

    After years of intense debate, SIND changed its position. “All of a sudden, they were very strong proponents for keeping the brains,” Erslev said, “actually saying this might be a very valuable resource, not only for the scientists, but for the sufferers of psychiatric illness because it might prove to benefit therapeutics down the line.”

    “For (SIND),” Kristensen said, “It was important where it was placed and to make sure that there would be some sort of control of the future use of the collection.”

    By the time it moved to Odense in 2018, the ethical debate was largely settled, and Wirenfeldt Nielsen became caretaker of the collection.

    A few years later, he would get a message from Søgaard. Was it possible, she asked, that he had a brain there belonging to a woman named Kirsten?

    In the search for what happened to her great aunt Kirsten, Søgaard realized there were clues all around her. But piecing together what exactly had happened to her grandmother’s sister was slow, filled with dead ends and false starts.

    Yet she was enthralled, and began officially reporting her journey for Kristeligt Dagblad, the Copenhagen-based newspaper where she worked – eventually bringing it to light in a series of articles.

    At one point, Søgaard decided to focus on a single word her grandmother had told her, the name of a psychiatric hospital: Oringe.

    “I opened my computer and I searched for ‘Oringe patient journals,’” she said. After putting in a request through the national archives, “I got an email that said, ‘Okay, we found something for you, come have a look if you want.’ … I felt this excitement … like, she’s out there.”

    Journalist Lise Søgaard made it her mission to find out what happened to her grandmother's little sister, Kirsten -- a journey that would take her places she never imagined. She shared that experience with CNN's Dr. Sanjay Gupta at her home outside Copenhagen in April 2022.

    That excitement was short-lived. At the national archives, they placed a mostly empty file in front of her. It wasn’t much to go on, but it confirmed Kirsten’s diagnosis of schizophrenia.

    Without another solid lead, Søgaard wondered where to go next. Then, almost in passing, as they looked through old family photos together, her mother said something that she’d never heard before.

    “She said, ‘You know, they might have kept her brain,’ and I said, ‘What?!’” Søgaard told CNN’s Dr. Sanjay Gupta at her house outside of Copenhagen. “And she told me what she knew about the brain collection.”

    At age 95, Søgaard’s grandmother, Inger, could still clearly picture visiting her little sister Kirsten in the hospital, after the symptoms she first started experiencing at age 14 continued to progress.

    Upon one visit, Inger remembered, “(Kirsten) was lying there, completely apathetic. She was not able to speak to us. … Another day we went to visit her, and she was gone from her room. They told us she had thrown a glass at a nurse, and they had sent her to the basement, to a room where they (restrained) her with belts. And we were not allowed to go in, but I saw her through a hole in the door; she was lying there, strapped up.”

    One floor of the Oringe psychiatric hospital is now a museum, which displays medical treatments and patient rooms such as this one.

    Inger felt confused and scared, she said, because it could have been anyone, including her, that might get “sick.”

    At Sankt Hans, one of the largest and oldest psychiatric hospitals in Denmark, Dr. Thomas Werge walks the same grounds he did as a child, when his own grandmother was hospitalized there. Now, he runs the Institute for Biological Psychiatry there, where he and his team study the biological causes that contribute to psychiatric disorders.

    A 2012 study found that roughly 40% of Danish women and 30% of Danish men had received treatment for a mental health disorder in their lifetimes – though Werge estimated that number would “almost certainly” be higher if the same study was done today. (By comparison, that same year, less than 15% of US adults received mental health services.) Among the other Nordic countries, including Sweden and Norway, Werge said the numbers would be comparable to Denmark’s, as there are “similar [universal] health care systems and standards for admission.”

    “Mental (health) disorders are all over,” he added. “We just do not recognize this when we walk around among people. Not everybody carries their pain on the outside.”

    For schizophrenia, there are no blood tests or biomarkers to signify its presence; instead, doctors must rely only on a clinical exam.

    Schizophrenia presents itself in what the World Health Organization (WHO) calls “significant impairments in the way reality is perceived,” causing psychosis that can include delusions, hallucinations, disorganized behavior or thoughts, and extreme agitation.

    Roughly one in 300 people are affected by schizophrenia worldwide, according to the WHO, but less than one-third of those will ever receive specialist mental health care.

    denmark cemetery of the brainless spc intl_00013202.png

    Visiting a ‘cemetery of the brainless’ in Denmark


    02:10

    – Source:
    CNN

    The standard treatment since the mid-1950s has been anti-psychotic drugs, which typically work by manipulating dopamine levels: the brain’s reward system. But, Werge said, it can come with a cost.

    “Schizophrenia and psychosis are linked to creativity,” he said. “So, when you try to inhibit the psychosis, you also inhibit the creativity. So, there’s a price for being medicated … Whatever causes all these problems for humans is also what makes us humans in the good sense.”

    Though there haven’t been many significant scientific breakthroughs regarding an understanding of the disease, researchers have confirmed that genetics and heritability play a significant role.

    According to Werge, the heritability estimate is as high as 80% – the same as height. “It’s not a surprise to people that if you have very tall parents … there’s a lot of genetics in that,” he said. “The genetic component is equally large in most of the mental disorders actually.”

    Those inherited genetic factors either come from the parents, he added, or can arise in a child even if the parents don’t carry the gene.

    Søgaard, who has two young children, said the genetic connection was not a driving motivator in her mission to find out what happened to Kirsten, but she has thought about what it means for herself and her family.

    When families reach out about possible relatives in the brain collection, “that’s an ethical dilemma that we need to take into consideration,” Wirenfeldt Nielsen said. In Søgaard’s case, she received approval for the Danish National Archives to check the set of black books that contain the names of every person whose brain is in the collection.

    There on the list was Kirsten’s name.

    “I got an email back [from the National Archives], and they scanned the page where Kirsten’s name was, and her birthday, and the day they received the brain. And in the column out to the left, there was a number,” Søgaard remembered. “Number 738.” She immediately wrote an email to Wirenfeldt Nielsen, asking if that number corresponded to the bucket with Kirsten’s brain.

    “I said, ‘Yes, that’s it,’” Wirenfeldt Nielsen recalled. But he also said he couldn’t be sure the bucket was there because a few are missing for unknown reasons. He ventured down to the basement storage room to verify it was there.

    On one of the rolling shelves sat bucket #738.

    Kirsten’s brain.

    Bucket #738 -- Kirsten's brain -- sits on a shelf among the rest of the brain collection in the basement at the University of Southern Denmark in Odense.

    When Søgaard first saw it, she felt compelled to hug the bucket.

    “I had learned a lot about Kirsten,” she said. “I feel some kind of connection … (and) I know the pain that she felt, and I know what she went through.”

    What Kirsten went through was another extraordinary beat in this incredible story, and the long history of psychiatric care in Denmark.

    As part of her treatment, Kirsten received what’s known commonly in Denmark as “the white cut.”

    In medical terms: a lobotomy.

    The procedure was an integral part of the country’s psychiatric history. During the time the brain collection was running from the 1940s until the early 1980s, Denmark reportedly did more lobotomies per capita than any other country in the world.

    01 denmark brain sanjay

    A look at the brain like you’ve never seen it before


    03:08

    – Source:
    CNN

    “It’s a very poor treatment, because you destroy a big part of the brain,” Wirenfeldt Nielsen said. “And it’s very risky, because you can kill the patient, basically – but they had nothing else to do.”

    Treatment options were limited, and in many ways extreme. Seizures were induced by placing electrodes on either side of the head; insulin shock therapy meant patients were administered large doses of insulin, reducing blood sugar and resulting in a comatose state; and the lobotomy, either transorbital – using a pick-like instrument inserted through the back of the eye to the front lobe – or prefrontal.

    The prefrontal lobotomy was pioneered by a Portuguese neurologist, Antonio Egas Moniz. Now considered barbaric, he actually won the Nobel Prize for the procedure in 1949.

    A tool is inserted into the frontal lobe, scraping away tracts of white matter – the reason behind the “white cut” moniker. “Emotional reactions … are located at least in part in the frontal lobe,” explained Wirenfeldt Nielsen, “so they thought that just by cutting (there), that could sort of calm the patient down.”

    Left: Portuguese neurologist Antonio Egas Moniz was awarded the Nobel Prize in 1949 for pioneering the prefrontal lobotomy.
Upper right: Lobotomies became a popular treatment option from the 1930s to the early 1950s. Here, a surgeon drills into a patient's skull at a hospital in England, 1946.
Lower right: By cutting tracts through brain matter in the frontal lobe, the belief was the lobotomy could treat symptoms of mental illness.

    In Kirsten’s case, Inger said there were glimpses of “the old Kirsten” before she got the white cut – but after that, she was gone. In 1951, the year after her lobotomy, Kirsten died.

    She was just 24 years old.

    On a metal table in a small, standalone building on the grounds of Oringe psychiatric hospital, Kirsten’s brain was removed, set into a small plastic bucket, placed in a wooden box, and shipped – by regular mail carrier – to the Institute of Brain Pathology at Risskov, to join the brain collection.

    Søgaard saw the metal table, where a white wooden block still sits on one end – where the heads were placed – and upon which small marks are still visible today. This is where the skulls were opened.

    The standalone building at Oringe (left) housing the autopsy room where Kirsten's brain was removed in 1951 still stands today, and includes the wooden boxes (right) that were once used to ship the brains to Risskov.

    Despite the graphic reminders, in reporting out this story both for herself, and for the newspaper, “it was important (for me) to not write a story that was a horror story,” she said, adding it was easy to look back and say, “How could you do that?”

    “I don’t think the doctors wanted to do bad. I think they actually wanted to do good. … I think the most ethical thing you can do is to make sure that you know exactly what you can do with these brains. And that’s what they’re doing now. They’re trying to find out, ‘How can they help us?’”

    There have been studies using the collection over the years, including a discovery in 1970 of what is now known as familial Danish dementia, and a new study is ongoing, focused on mRNA in the brains, by Danish researcher Betina Elfving.

    For the most part, the brains represent untapped, enormous potential. Yet the one in bucket #738 has already done something extraordinary, thanks in large part to Søgaard herself. She worked to break the cycle of stigma surrounding mental health disorders by sharing her most personal, intimate family details with the world.

    “(My grandmother) expressed gratitude,” Søgaard said. “She also said, ‘I feel like I’m moving closer to my sister now.’”

    [ad_2]

    Source link

  • Landmark Study Seeks Participants With VCFS-Related Psychosis to Help Create Biobank of Human Neural Tissue to Develop Innovative Treatments

    Landmark Study Seeks Participants With VCFS-Related Psychosis to Help Create Biobank of Human Neural Tissue to Develop Innovative Treatments

    [ad_1]

    The Virtual Center for Velo-Cardio-Facial Syndrome collaborates with the Center for Precision Neuropsychiatry based in the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons

    Press Release



    updated: Oct 23, 2019

    A landmark study is calling for at least 50 people in the U.S. with Velo-Cardio-Facial Syndrome (VCFS)-related psychosis to provide blood samples to create the world’s largest VCFS biobank to date of tiny spheres of neural tissue called “cerebral organoids.” Given that current medications used to treat VCFS-related psychosis are largely ineffective, researchers hope to discover novel and effective treatments for this condition by studying these cerebral organoids.

    The Center for Precision Neuropsychiatry, founded by Sander Markx, M.D., and based in the Department of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons, is collaborating in this research with the Virtual Center for Velo-Cardio-Facial Syndrome, founded by Robert J. Shprintzen, Ph.D. VCFS was first described in 1978 by Dr. Shprintzen and he was the first to report that psychosis is a common clinical feature of the syndrome.

    VCFS, also known as DiGeorge syndrome, Shprintzen syndrome, and 22q11.2 Deletion Syndrome, is caused by a deletion of DNA from one copy of a specific region of chromosome 22 containing more than two dozen genes. It is the most common genetic multiple congenital anomaly syndrome and the most common genetic cause of psychosis. About one-third of people with VCFS develop psychosis and 1-2% of all patients with schizophrenia have a 22q11.2 microdeletion.

    The researchers hope to learn more about how psychosis develops, how better treatments might be identified for this condition, and why people with VCFS develop mental illness at such a high rate. Ultimately, their intent is to develop effective treatments for people at high genetic risk for developing psychiatric illness.

    A total of 50 participants with VCFS who are genetically confirmed to have a 22q11.2 deletion and are diagnosed with a psychotic disorder will be asked to provide a small blood sample for this study. In addition, the researchers will ask an unaffected first-degree family member of the donor (either same-sex sibling or same-sex parent) to contribute a blood sample to serve as a control subject. Phlebotomists will visit the participants to draw the blood in the comfort of their homes or location of their choice.

    While some of the study participants will come from a pool of cases currently registered at the Virtual Center, more may be needed: the study is open to interested parties diagnosed with VCFS who live in the 48 U.S. contiguous states. VCFS patients who meet the requirements and want to participate in the study can register at www.vcfsmentalillness.org or email info@vcfscenter.org for further information.

    Sander Markx, M.D., Assistant Professor of Psychiatry at Columbia University Vagelos College of Physicians and Surgeons and Principal Investigator, has a long-standing interest in VCFS. “We need to reach a better understanding of what goes on in the developing brain that ultimately gives rise to the increased risk for psychosis in patients with this genetic condition,” he states. “Improved understanding will help us develop novel, more efficacious medications that target specific disease mechanisms so we can achieve better clinical outcomes with fewer side effects for our patients. We hope that our process will guide future treatment for mental and cognitive disorders and ultimately reveal basic biology of debilitating disorders, such as schizophrenia and autism.”

    As Robert J. Shprintzen, Ph.D., President and Chairman of the Board at the Virtual Center for VCFS, observes, “This study is of significant importance for sufferers of VCFS all over the world. Although VCFS is the most common genetic cause of psychosis and the genetic mutation that causes VCFS has been known for more than 25 years, so far, treatments for these problems have largely been ineffective. We expect that our collaborative research with eminent colleagues at one of the most highly regarded psychiatric facilities in the world will translate to more effective patient care.”

    Additional information about the blood draw

    The blood sample from the subject and his/her relative will be used to develop iPSCs and organoids to better understand VCFS biology and responses to medications. For each case, it will be determined whether he/she suffers from a psychotic condition. Following this initial study, the team plans to run clinical trials of medications that show promise in the organoid response.

    The study will use induced pluripotent stem cells (iPSCs) obtained from donor blood. White blood cells are reprogrammed to become stem cells and those stem cells are grown into cerebral organoids, which will be exposed to drug libraries to determine how the brain tissue responds. This type of research, called translational research, yields results that could ultimately help lead to the identification and development of new treatments for this debilitating condition.

    About The Virtual Center for Velo-Cardio-Facial Syndrome, Inc.

    The Virtual Center for Velo-Cardio-Facial Syndrome, Inc. is an open-access 501(c)3, internet-based charitable organization that provides personalized information to people whose lives have been touched by VCFS and who are seeking applicable research and clinical expertise regarding the management of the syndrome. There is no charge for this service, which is funded by voluntary donations.

    About Velo-Cardio-Facial Syndrome

    Velo-Cardio-Facial syndrome (VCFS) is the most common genetic multiple congenital anomaly disorder in humans. It is caused by a microdeletion of DNA from chromosome 22, typically encompassing approximately 40 genes. It is known by a number of other names, including DiGeorge syndrome, conotruncal anomalies face syndrome, Sedlačková syndrome and, more recently, 22q11.2 Deletion Syndrome. Approximately 200 distinct congenital anomalies and disorders are associated with VCFS. Recent data has shown that more than 1 in every 1,000 pregnancies have the deletion from chromosome 22 that causes VCFS. Because so many problems can occur in people with VCFS, it is difficult to have all of the specialists with special knowledge of the syndrome needed for required diagnosis and management together in one location. The Virtual Center allows experts to spread knowledge and information pertinent to individual cases anywhere in the world, thereby sharing expertise and educating local practitioners at the same time.

    Press Contacts:

    The Virtual Center for Velo-Cardio-Facial Syndrome, Inc.

    Robert J. Shprintzen, Ph.D.
    E-mail: info@vcfscenter.com
    Tel: 315-559-4685
    Web: www.vcfsmentalillness.org

    Fortress Strategic Communications for The Virtual Center for Velo-Cardio-Facial Syndrome, Inc.

    Evan Bloom, CEO
    Tel: 315-744-4912
    E-mail: evan@fortresscomms.com
    Web: www.fortresscomms.com

    Source: The Virtual Center for Velo-Cardio-Facial Syndrome, Inc.

    [ad_2]

    Source link